Skip to content

KLRS KLRS Operating Income

Operating Income at other companies

Amgen logo
AmgenAMGN
$2.67B+126%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$642.9M+8.7%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
-$87.23M-78.6%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$93.34M-46.0%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$59.78M-1.2%
AbbVie logo
AbbVieABBV
$3.99B+6.9%

Other financials

Income statement

See full
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's operating income?
KLRS (KLRS) reported operating income of -$11.83M in Q1 2026.
How has KLRS's operating income changed year-over-year?
KLRS's operating income decreased by 14.3% year-over-year, from -$10.35M to -$11.83M.
What is the long-term trend for KLRS's operating income?
Over 3 years (2021 to 2025), KLRS's operating income has grown at a -35.2% compound annual growth rate (CAGR), from -$169.82M to -$46.15M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.